Cardiac Drug Development Guide
In Vitro Neurotoxicology: Principles and Challenges, edited by Evelyn Tiffany-Castiglioni, 2004
Apoptosis Methods in Pharmacology and Toxicology: Approaches to Measurement and Quantification, edited by Myrtle A. Davis, 2002
Cardiac Drug Development Guide

Edited by

Michael K. Pugsley

Department of Pharmacology, Forest Research Institute, Jersey City, NJ
Preface

*Cardiac Drug Development Guide* outlines, in detail, the therapeutics of cardiac medicine currently at the cutting edge of scientific research and development around the world. This volume integrates basic and clinical cardiac pharmacology by combining, for the first time, both classical and molecular aspects of therapeutic drug development. The chapters comprise a broad spectrum of therapeutic areas and hence involve a comprehensive discussion of molecular, biochemical, and electrophysiological concepts based on years of in vitro as well as in vivo pharmacological studies. In addition, the latter part of the book includes comprehensive clinical cardiac chapters that describe important topics in molecular medicine. These chapters also discuss current clinical therapeutic trends in medicine and provide an evaluation of the efficacy of novel drugs in these areas.

*Cardiac Drug Development Guide* has many distinctive and outstanding features that set it apart from other cardiac pharmacology books. This book introduces topics in an easily understandable format for researchers in many varying disciplines by integrating and thereby simplifying concepts not usually discussed across a broad range of cardiac disciplines and in a highly technical field. Each chapter not only introduces and describes the physiology, pharmacology, and pathophysiology of the disease, but also overviews the clinical implications of drug development, what stages these areas are currently in, and also reviews some of the methodologies involved in drug discovery and development. As a result, this book provides a comprehensive overview of the most advanced procedures in cardiac pharmacology today. It is hoped that *Cardiac Drug Development Guide* provides useful information to graduate students, academic scientists, clinicians, and those researchers in the pharmaceutical and biotechnology sectors of the drug industry.

*Cardiac Drug Development Guide* was fashioned from my many years of experience both learning pharmacology as a graduate student in Canada and as an MRC postdoctoral research fellow and applying that knowledge in industry as a senior pharmacological scientist. I wish to thank all my colleagues around the world for contributing to this book and to my family, especially my loving wife, Suzanne, for all their support.

*Michael K. Pugsley*
Contents

Preface ........................................................................................................................................... v
Contributors ................................................................................................................................. ix

I INTRODUCTION
1 Cardiac Drug Development: From Animal Models to Clinical Trials
   Michael K. Pugsley ..................................................................................................................... 3

II NOVEL MOLECULAR TARGETS FOR CARDIAC DRUG DEVELOPMENT
2 The Role of Cardiac Pacemaker Currents in Antiarrhythmic Drug Discovery
   David A. Saint ........................................................................................................................... 27
3 Oxygen Free Radicals in Heart Disease: Novel Therapies
   Elizabeth Roth and Laszlo Hejjel .......................................................................................... 47
4 Mitogen-Activated Protein Kinases-Mediated Signaling in Cardiac Pathology: A Perspective of Novel Therapeutic Targets?
   Tanya Ravingerova, Miroslav Barancik, and Monika Strniskova ....... 67
5 Development of Anti-Inflammatory Drugs for Cardiovascular Disease
   Melanie B. Smith and David J. Lefer ....................................................................................... 87
6 Development and Use of Platelet Glycoprotein Antagonists in Heart Disease
   Joel S. Bennett .......................................................................................................................... 107
7 The Sodium–Hydrogen Exchange System in the Heart: A Target for the Protection of the Ischemic and Reperfused Heart and Inhibition of Heart Failure
   Morris Karmazyn ..................................................................................................................... 123
8 Nitric Oxide and Cardiac Ischemia
   Mariarosaria Bucci, Inmaculada Posadas Mayo,
   and Giuseppe Cirino ............................................................................................................... 141

III FUNCTIONAL ENDPOINTS EVALUATING CARDIAC DRUG ACTIVITY
9 Ionic Mechanisms of Atrial Fibrillation
   J. Christian Hesketh and David Fedida .................................................................................. 163
10 Targeting Ischemic Ventricular Arrhythmias
    Michael J. A. Walker and Leon J. Guppy ............................................................................ 175
11 Biochemical Mediators of Ventricular Arrhythmias in Ischemic Heart Disease
    Hugh Clements-Jewery and Michael J. Curtis ................................................................. 203
12 Heterologous Expression Systems and Screening Technologies in Ion Channel Drug Discovery
Maurizio Tagliatela ................................................................. 227

13 Molecular Diversity of Ion Channels in the Mouse Heart: A Suitable Model for Cardiac Drug Development?
Jeanne M. Nerbonne ............................................................ 245

14 Delayed Protection of the Myocardium: A Novel Therapeutic Window for Cardiac Drug Development
László Szekeres and James Parratt ........................................ 271

IV CLINICAL ASPECTS IN CARDIAC DRUG DEVELOPMENT
15 Cardiac Troponin Testing for Detection of Myocardial Infarction: Clinical Utility and Analytical Issues
Fred S. Apple ........................................................................... 297

16 A Genetic Basis for Cardiac Arrhythmias: Current Status and the Future
Jeffrey A. Towbin, Matteo Vatta, Hua Li, and Neil E. Bowles .......... 317

17 Myocardial Adenoviral Vector Delivery for Cardiovascular Gene Therapy
Hendrik T. Tevaearai, Andrea D. Eckhart, and Walter J. Koch .......... 351

18 The Role of Pharmacometrics in Cardiovascular Drug Development
Paul J. Williams, Amit Desai, and Ene Ette .................................. 365

19 Gender Differences in Heart Failure: Concerns for Drug Development
Mark A. Sussman ...................................................................... 389

20 Angiogenesis Therapies for Coronary Artery Disease: Trials and Tribulations
Michael Simons ....................................................................... 407

Index .......................................................................................... 421
Contributors

FRED S. APPLE • Clinical Laboratories, Hennepin County Medical Center
   and Department of Laboratory Medicine and Pathology, University of Minnesota,
   School of Medicine, Minneapolis, MN
MIROSŁAV BARANCIK • Department of Cardiovascular Physiology, Institute
   for Heart Research, Slovak Academy of Sciences, Slovak Republic
JOEL S. BENNETT • Hematology-Oncology Division, Department of Medicine,
   University of Pennsylvania School of Medicine, Philadelphia, PA
NEIL E. BOWLES • Department of Pediatrics, Baylor College of Medicine, Houston, TX
MARIA ROSARIA BUCCI • Department of Experimental Pharmacology,
   Faculty of Pharmacy, University of Naples, Naples, Italy
GIUSEPPE CIRINO • Department of Experimental Pharmacology,
   Faculty of Pharmacy, University of Naples, Naples, Italy
HUGH CLEMENTS-JEWERY • Centre for Cardiovascular Biology and Medicine,
   King’s College London, London, UK
MICHAEL J. CURTIS • Centre for Cardiovascular Biology and Medicine,
   King’s College London, London, UK
AMIT DESAI • Department of Pharmacy Practice, School of Pharmacy,
   University of the Pacific, Stockton, CA
ANDREA D. ECKHART • Department of Surgery, Duke University Medical Center,
   Durham, NC
ENE ETTE • Vertex Pharmaceutical Corporation, Cambridge, MA
DAVID FEDIDA • Department of Physiology, University of British Columbia,
   Vancouver, Canada
LEON J. GUPPY • Department of Pharmacology and Therapeutics,
   University of British Columbia, Vancouver, Canada
LASZLO HEJJEL • Division of Cardiac Surgery, Heart Institute, Medical Faculty,
   University of Pecs, Pecs, Hungary
J. CHRISTIAN HESKETH • Department of Experimental Medicine, Cardiome Pharma
   Corporation, Vancouver, Canada
MORRIS KARMAZYN • Department of Physiology and Pharmacology,
   University of Western Ontario, Ontario, Canada
WALTER J. KOCH • Department of Surgery, Duke University Medical Center,
   Durham, NC
DAVID J. LEFER • Department of Molecular and Cellular Physiology,
   Louisiana State University Health Sciences Center, Shreveport, LA
HUA LI • Department of Pediatrics, Baylor College of Medicine, Houston, TX
JEANNE M. NERBONNE • Department of Molecular Biology and Pharmacology, Washington University Medical School, St. Louis, MO

JAMES PARRATT • Department of Physiology and Pharmacology, University of Strathclyde, Strathclyde Institute for Biomedical Sciences, Glasgow, Scotland

INMACULADA POSADAS MAYO • Department of Experimental Pharmacology, Faculty of Pharmacy, University of Naples, Naples, Italy

MICHAEL K. PUGSLEY • Department of Pharmacology, Forest Research Institute, Jersey City, NJ

TANYA RAVINGEROVA • Department of Cardiovascular Physiology, Institute for Heart Research, Slovak Academy of Sciences, Slovak Republic

ELIZABETH ROTH • Department of Experimental Surgery, Medical Faculty, University of Pecs, Pecs, Hungary

DAVID A. SAINT • Cellular Biophysics Laboratory, Department of Physiology, University of Adelaide, Adelaide, Australia

MICHAEL SIMONS • Section of Cardiology, Dartmouth Medical School, Dartmouth Hitchcock Medical Center, Hanover, NH

MELANIE B. SMITH • Department of Molecular and Cellular Physiology, Louisiana State University Health Sciences Center, Shreveport, LA

MONIKA STRNISKOVÁ • Department of Cardiovascular Physiology, Institute for Heart Research, Slovak Academy of Sciences, Slovak Republic

MARK A. SUSSMAN • Division of Molecular Cardiovascular Biology, The Children’s Hospital and Research Foundation, Cincinnati, OH

LÁSZLÓ SZEKERES • Department of Pharmacology and Pharmacotherapy, University of Szeged, Szeged, Hungary

MAURIZIO TAGLIALATELA • Section of Pharmacology, Department of Neuroscience, School of Medicine, University of Naples Federico II, Naples, Italy

HENDRICK T. TEVAEARAI • Department of Surgery, Duke University Medical Center, Durham, NC

JEFFREY A. TOWBIN • Department of Pediatrics, Cardiovascular Sciences and Molecular Human Genetics, Baylor College of Medicine, Houston, TX

MATTEO VATTA • Department of Pediatrics, Baylor College of Medicine, Houston, TX

MICHAEL J. A. WALKER • Department of Pharmacology and Therapeutics, University of British Columbia, Vancouver, Canada

PAUL J. WILLIAMS • Department of Pharmacy Practice, School of Pharmacy, University of the Pacific, Stockton, CA